Latest news with #BoehringerIngelheim
Yahoo
6 hours ago
- Health
- Yahoo
Biomarkers may address unmet needs of idiopathic pulmonary fibrosis treatment
Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease characterised by the accumulation of scar tissue in the lungs, leading to respiratory failure. The current treatment approaches for IPF include Boehringer Ingelheim's Ofev and Roche's Esbriet. However, despite advancements in understanding and managing IPF, current treatments may not address several unmet needs in this space, particularly regarding detection, disease progression, therapeutic targets, biomarkers, and disease management options (Carita Bramhill et al, 2024). Identifying biomarkers that can contribute to early diagnosis and differentiate IPF from other interstitial lung diseases will be key, as they will enable more tailored approaches and disease management for different patient groups. Additionally, the prediction of disease progression may also further contribute to improving treatment management (Hong-Jing Zhu et al, 2024). Biomarkers may include promising proteins such as serum amyloid A3 (SAA3), which has been implicated in lung inflammation and worsening of lung fibrosis (Yuyu Yang et al, 2025). Key findings from the study by Yang and colleagues indicated that higher levels of SAA3 were associated with more severe lung damage in IPF patients, which may suggest that targeting SAA3 could be a promising new approach for treating IPF and similar fibrotic diseases. Such discoveries will also address other important unmet needs such as the identification of new therapeutic targets and agents that may be able to further target underlying mechanisms of fibrosis and inflammation in IPF. They may also treat symptoms, the reduction of which is key in the majority of IPF patients. Addressing the unmet needs in the IPF space requires a multifaceted approach that includes the identification and validation of biomarkers for diagnosis, prognosis, and treatment response. Continued research into the molecular mechanisms of IPF such as the role of SAA3 proteins will be crucial for developing innovative therapies that can improve patient outcomes and quality of life. "Biomarkers may address unmet needs of idiopathic pulmonary fibrosis treatment" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Daily News Egypt
a day ago
- Health
- Daily News Egypt
Boehringer Ingelheim partners with General Organization of Veterinary Services to ‘Stop Rabies' in Egypt
In a first-of-its-kind public-private partnership, the General Organization of Veterinary Services (GOVS) and Boehringer Ingelheim, a leading research-driven biopharmaceutical company have signed a Memorandum of Understanding (MoU) to advance efforts to eliminate dog-mediated human rabies. This partnership aims to address public health risks associated with rabies in Egypt. The signing of this agreement reflects a shared commitment across government and institutional stakeholder to protect the health of Egyptian citizens and maintain environmental and public health balance throughout the country. Egypt has made progress in combating zoonotic diseases through vaccination campaigns, awareness efforts, and the expansion of cooperation protocols with partners from the private sector and civil society. The GOVS, emphasizes the importance of cross-sector partnerships, which combine scientific and practical expertise with logistical and administrative support to achieve effective and sustainable results in reducing the spread of rabies—particularly in rural areas and regions with high animal density. Rabies is a viral zoonotic disease that attacks the central nervous system and is fatal once clinical symptoms appear. Transmitted primarily through dog bites, it remains a preventable yet deadly global threat, causing around 59,000 human deaths worldwide each year. The agreement, signed on July 22 at the GOVS headquarters in Ismailia, marks a significant step in addressing the ongoing threat of rabies on the Egyptian community. The MoU was signed by Dr. Hamed Moussa Al-Aqnas, Chairman of the General Organization for Veterinary Services and Mahmoud El Mahdy, Country Head of Animal Health for North, East, and West Africa at Boehringer Ingelheim. Dr. Hamed Moussa Al-Aqnas, Chairman of the General Organization for Veterinary Services said: 'Rabies remains one of the most serious public health threats, despite being preventable. At GOVs, we are committed to promoting the health and well-being of animals in Egypt, while also safeguarding human health from animal-related diseases. Through stronger cross-sector collaboration and by aligning with the global strategy to eliminate rabies by 2030, we aim to advance Egypt's national response and deliver sustainable impact. ' 'Public engagement is a key component in rabies elimination efforts. We aim to increase the community's understanding of how rabies is transmitted and the serious risks it poses, with a particular focus on protecting our youth who are among the most vulnerable and often come into contact with stray dogs during play. In parallel, we are committed to promoting responsible pet ownership by emphasizing the importance of vaccinating domestic dogs to safeguard both their owners and the wider community,' added Dr. Moussa. Following the agreement, GOVS and Boehringer Ingelheim will be the primary drivers of the 'Elimination of Dog-Mediated Human Rabies', an initiative by the Ministry of Agriculture and Land Reclamation (MoALR). The two parties will collaborate to conduct comprehensive vaccination campaigns targeting stray dogs against rabies across Egypt, starting in Ismailia. 'Despite being a vaccine-preventable disease, rabies continues to be a global threat and is responsible for the death of thousands of people every year, with a large proportion of victims being children. As a global leader in rabies prevention, we have the expertise and tools needed to support rabies elimination efforts and help protect communities from dog-mediated rabies. However, our impact is greatly amplified through strategic public partnerships that empower us to drive greater change. We look forward to working closely with the General Organization of Veterinary Services to address the threat of rabies in Egypt and help safeguard both children and adults from this devastating disease, contributing to a healthier and safer environment for both humans and dogs,' said Mahmoud El Mahdy, Country Head of Animal Health for North, East, and West Africa at Boehringer Ingelheim. In addition to conducting rabies vaccination campaigns, the agreement includes raising awareness about rabies, its dangers, and the importance of prevention. This will be achieved through various mediums, including local community events and educational programs in academic settings. The partnership is part of Boehringer Ingelheim's global 'Stop Rabies' initiative, which aims to eliminate dog-mediated rabies through a holistic approach focused on vaccination, education, and surveillance. With a commitment to providing 500 million vaccine doses and educating 15 million children by 2038, the company is working closely with governments, NGOs, veterinarians, and communities to address the disease at its source. In Egypt, this partnership with GOVS marks a critical step toward that global goal, starting in Ismailia and aiming to create long-term, community-driven impact. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim – Life Forward | Boehringer Ingelheim .
BBC News
4 days ago
- Business
- BBC News
German pharma firm signs deal worth up to $1bn with QUB spin out
A medical technology company founded by Queen's University academics has signed a licensing agreement with a major pharmaceutical firm which could ultimately be worth up to $1bn (£744.1m).Re-Vana Therapeutics, which was set up in 2016, develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of care for major benefit of its technology is that it reduces the number of eye injections patients require making them more likely to follow their Ingelheim, a German pharmaceutical firm, is licensing the drug delivery system to combine it with its eye medications. The German firm will take responsibility for regulatory approvals and global commercialization of products developed using the Re-Vana Ingelheim said the deal involves "upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1bn for the initial three targets, in addition to royalty payments on net sales".Re-Vana was founded by Professor Raj Thakur and Professor David Jones with investors including Qubis, the commercialisation arm of Queen's company is now based in the US but still has its research base in O'Rourke, Re-Vana's Chief Executive Officer, said the collaboration with Boehringer Ingelheim is a "transformational moment".The deal has also been welcomed by NI Secretary of State Hillary Benn who said it "represents a huge vote of confidence in Northern Ireland's innovation and skills".
Yahoo
4 days ago
- Business
- Yahoo
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people's way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana's drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health. 'We're looking forward to team up with Re-Vana to push the boundaries of what's possible in eye health,' said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. 'Together, we want to tackle the limits of today's treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.' 'The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,' said Michael O'Rourke, Re-Vana Chief Executive Officer. 'By combining our extended-release platform with Boehringer Ingelheim's world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.' Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana's feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at (Global) or (UK). About Re-Vana Therapeutics Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen's University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset. Learn more at Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Media Contacts Boehringer Ingelheim: Dr. Reinhard MalinBoehringer Ingelheim Corporate Center GmbH Innovation Unit/Bio Comms, Corp. Affairs Media + PR press@ Linda RuckelBoehringer IngelheimInnovation Unit Re-Vana: Michele Gray Gray Communications, LLCMichele@ 917 449 9250Sign in to access your portfolio
Hamilton Spectator
24-07-2025
- Business
- Hamilton Spectator
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported positive growth in the first half of 2025, with group net sales growing by 6.3%* to EUR 14.0 billion. This performance was driven by strong demand for key products in Human Pharma, namely JARDIANCE® with EUR 4.3 billion and OFEV® with EUR 2.0 billion, which continue to make a meaningful difference for patients worldwide. Building on this momentum, the company is advancing its late-stage pipeline with several therapies nearing regulatory approval. Among these are zongertinib for HER2-mutant lung cancer and nerandomilast for pulmonary fibrosis, both of which recently delivered positive pivotal results and are progressing towards potential launches in the second half of 2025. 'At Boehringer Ingelheim, our commitment to transforming lives for generations is more than a mission — it's a responsibility we carry forward every day. Therapies like JARDIANCE® and OFEV® continue to make a real difference to patients — they exemplify what's possible when true innovation addresses unmet medical needs,' said Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma. 'At the same time, we're making strong progress across our pipeline — from obesity to liver and kidney health — with the goal of redefining standards of care. As we prepare for the potential launches of zongertinib and nerandomilast later this year, we remain focused on delivering meaningful solutions. We understand the urgency behind every patient's need, and we're acting with speed and purpose to meet it.' Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: 'In a volatile environment, we are delivering according to plan, with robust sales performance across our portfolio in human and animal health. As we prepare for major launches, we are investing more than ever – focusing on speed, scale, and impact to ensure we are ready to deliver innovative therapies to change the course of serious diseases. Beyond the excitement of new launches, we also see substantial growth potential in our established products, particularly with JARDIANCE®, which continue to make a meaningful difference for patients worldwide.' Human Pharma In the first half of 2025, Boehringer Ingelheim's Human Pharma business grew 5.7%* reaching EUR 11.3 billion in net sales. Growth was driven by solid global demand for key products, including EUR 4.3 billion in sales from JARDIANCE®, the treatment of chronic kidney diseases, type 2 diabetes and heart failure, and EUR 2.0 billion in sales from OFEV®, which is used to treat idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases. Boehringer Ingelheim's human pharma pipeline is strong, with over ten new Phase II and III trials starting in the next 12 to 18 months across our multiple therapeutic areas. These could lead to major product launches over the next five years, offering the potential to transform millions of lives. U.S. launches for zongertinib and nerandomilast are expected in the second half of 2025, pending FDA approval. Zongertinib, a targeted therapy for HER2-mutant advanced non-small cell lung cancer (NSCLC), showed durable response and clinically meaningful results in previously treated patients, with more than 70% of patients experiencing a tumor response. It is under regulatory review in U.S., Japan and China and being studied as a first-line treatment in a global Phase III trial. If approved, it would become the first orally administered targeted treatment for previously treated HER2-mutated lung cancer patients. Nerandomilast, a potential therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), significantly slowed lung-function decline in the two FIBRONEER™ Phase III trials. It was well tolerated, with discontinuation rates comparable to placebo. Regulatory submissions have been made in the U.S., EU, China and Japan. The company also launched a Phase III trial for our DPP1/CatC inhibitor verducatib (BI 1291583) to evaluate its potential in treating bronchiectasis. Verducatib received FDA breakthrough therapy designation in 2024. In cardiovascular, renal, and metabolic (CRM) diseases, Boehringer Ingelheim started two new Phase III trials under the ongoing EASi trial program. In these trials, the company is investigating the potential benefits of an aldosterone synthase inhibitor/SGLT2i therapy in people with chronic heart failure and for cardiovascular risk reduction in people with type 2 diabetes, high blood pressure and cardiovascular disease. To support future launches and continued growth, the company is continuing to strengthen its global supply network. A key milestone is the EUR 300 million investment in its Yamagata site in Japan, with the opening of a new production unit, infrastructure measures and groundbreaking for an additional facility began in June. This expansion will position Japan as a critical production hub for the Asia and Oceania regions. At the same time Boehringer continues to strengthen its local production network in the USA, building on existing partnerships. Animal Health In the first six months of 2025, Boehringer Ingelheim's Animal Health Business delivered strong growth, with net sales increasing by 7.6%* to EUR 2.6 billion. This performance was driven by continued momentum in the parasiticide portfolio, particularly the NEXGARD® brand, which grew by 7.9%*. A key growth driver in Europe was BULTAVO 3™, a newly launched vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first vaccine to prevent both clinical signs and mortality from BTV-3 and has been licensed in several European countries. The company also expanded its vaccine portfolio with the launch of VAXXITEK® HVT+IBD+H5, a trivalent poultry vaccine, offering protection against Marek's disease, Infectious Bursal Disease, and H5 avian influenza in a single shot. It was first introduced in Egypt in early 2025 and is designed for administration directly at the hatchery, providing early protection for chicks. In the companion animal segment, Boehringer Ingelheim entered a strategic digital health collaboration with Eko Health to improve early detection of heart disease in dogs. The partnership combines Boehringer's expertise in canine cardiology with Eko's AI-powered stethoscope technology, aiming to launch a dedicated mobile app for veterinarians in 2026. Outlook As Boehringer Ingelheim enters the second half of 2025, the company is well-positioned to build on its first-half year performance and expects a positive year-on-year increase in net sales. With major product launches, a robust pipeline, and strategic investments in R&D and manufacturing, Boehringer Ingelheim is set to expand its global impact and bring innovative health solutions to more patients and animals worldwide. Visit our half-year financial highlights page HERE . * on a comparable basis (adjusted for currency and other effects) Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at . Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
